Axatilimab
- Generic Name
- Axatilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2155851-88-8
- Unique Ingredient Identifier
- R96Z451BMC
- Background
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Graft versus Host Disease Market to Increase at a CAGR of
Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period
The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.
Ruxolitinib May Elicit Skin/Joint, Chronic GVHD Responses
Ruxolitinib showed high rates of skin/joint responses, overall cGVHD responses, low NRM, high FFS, and improved PROs in refractory sclerotic cGVHD patients. 49% achieved PR in skin/joints at 6 months, with 47% overall cGVHD PR. Treatment failure was 20.8%, NRM 2.2%, and FFS 77.1% at 12 months. Ruxolitinib was well-tolerated with no new safety signals.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath